Our lead candidate, AMI463, has received Orphan Drug Designation from the European Medicines Agency (EMA) and from the U.S. Food and Drug Administration (FDA) for the treatment of Soft-Tissue Sarcoma (STS). We are currently advancing its development for Rhabdomyosarcoma (RMS), a rare and challenging cancer predominantly found in soft tissues like skeletal muscle or occasionally in hollow organs, indication for which AMI463 has obtained the Rare Pediatric Disease Designation (RPDD) from the FDA. This development underscores our commitment to addressing areas of significant unmet medical need. Furthermore, we recognize the broader potential of AMI463 in treating various forms of soft-tissue sarcoma and other solid tumors in both pediatric and adult patients.